Immune Design reports Phase II STS data for CMB305

Immune Design Corp. (NASDAQ:IMDZ) reported interim data from a Phase II trial evaluating CMB305 (ID-CMB305) plus Tecentriq atezolizumab compared to Tecentriq alone to treat soft tissue sarcoma (STS). In a prespecified interim analysis of 36 evaluable patients, CMB305 plus Tecentriq led to a disease control rate (DCR) of 61%, including 1 partial response, vs. 28% and no partial responses for Tecentriq alone. Median progression-free survival (PFS), a co-primary endpoint, was 2.6 months for the combination arm vs. 1.4 months for Tecentriq alone.

In the full study population (n=88), CMB305 plus Tecentriq led to a DCR of 57%, including 3 partial responses, vs. 38% and no partial responses for Tecentriq alone. Additionally, the company said there was a trend towards improved overall survival (OS), a co-primary endpoint, in patients with an induced anti-cancer/testis antigen 1B (NY-ESO-1; CTAG1B) T cell or antibody response who received CMB305 plus Tecentriq compared to patients without induced T cells or antibodies. The combination was well tolerated...